Top

Published in:

01-03-2018 | Geriatric Oncology (AR MacKenzie, Section Editor)

Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients

Authors: Kah Poh Loh, Colin McHugh, Supriya G. Mohile, Karen Mustian, Marie Flannery, Heidi Klepin, Rebecca Schnall, Eva Culakova, Erika Ramsdale

Published in: Current Oncology Reports | Issue 3/2018

Abstract

Purpose of Review

Older adults with cancer have complex medical needs and often experience higher rates of treatment-related toxicities compared to their younger counterparts. The advent of health information technologies can address multiple gaps in the care of this population. We review the role of existing and emerging technologies in facilitating the use of comprehensive geriatric assessment (CGA) in routine clinics, promoting symptom reporting, and monitoring medication adherence.

Recent Findings

Increasingly, studies demonstrate the feasibility of implementing electronic CGA in routine oncology practices. Evidence also suggests that electronic symptom reporting can improve outcomes in patients with cancer. In addition, technology devices can be used to promote adherence to cancer therapy.

Summary

There are many opportunities for information technology to be integrated into the management and treatment of older adults with cancer. However, further evaluation of these technologies is needed to ensure that they meet the needs of the targeted end users.

Berger NA, Savvides P, Koroukian SM, Kahana EF, Deimling GT, Rose JH, et al. Cancer in the elderly. Trans Am Clin Climatol Assoc. 2006;117:147–56.

Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3457–65.CrossRef

Mandilaras V, Wan-Chow-Wah D, Monette J, Gaba F, Monette M, Alfonso L. The impact of cancer therapy on cognition in the elderly. Front Pharmacol. 2013;4:48.CrossRefPubMedPubMedCentral

Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 Suppl 2):18–24.PubMed

Loh KP, Janelsins MC, Mohile SG, Holmes HM, Hsu T, Inouye SK, et al. Chemotherapy-related cognitive impairment in older patients with cancer. J Geriatr Oncol. 2016;7(4):270–80. https://doi.org/10.1016/j.jgo.2016.04.008.

Karuturi M, Wong ML, Hsu T, Kimmick GG, Lichtman SM, Holmes HM, et al. Understanding cognition in older patients with cancer. J Geriatr Oncol. 2016;7(4):258–69. https://doi.org/10.1016/j.jgo.2016.04.004.

Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am J Public Health. 2010;100(S1):S105–12. https://doi.org/10.2105/AJPH.2009.162982.CrossRefPubMedPubMedCentral

Loh KP, Soto-Perez-de-Celis E, Hsu T, de Glas NA, Battisti NML, Capucine B, et al. What every oncologist should know about geriatric assessment for older patients with cancer: Young SIOG position paper. J Oncol Pract. 2018. (in press).

Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998–2005. https://doi.org/10.1002/cncr.21422.

10.

Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.CrossRefPubMed

11.

Brody EM, Kleban MH. Physical and mental health symptoms of older people: who do they tell? J Am Geriatr Soc. 1981;29(10):442–9. https://doi.org/10.1111/j.1532-5415.1981.tb01746.x.CrossRefPubMed

12.

Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The accuracy of pain and fatigue items across different reporting periods. Pain. 2008;139(1):146–57. https://doi.org/10.1016/j.pain.2008.03.024.CrossRefPubMedPubMedCentral

13.

Bender CM, Gentry AL, Brufsky AM, Casillo FE, Cohen SM, Dailey MM, et al. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum. 2014;41(3):274–85. https://doi.org/10.1188/14.ONF.274-285.

14.

Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.CrossRefPubMed

15.

The National Comprehensive Cancer Network®. 2015. Older adult oncology: NCCN guidelines. [ONLINE] Available at: http://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. [Accessed 09 January 16].

16.

Pew Research Center. Americans’ Internet AccessL 2000-2015. 2015 June. Available at: http://www.pewinternet.org/2015/06/26/americans-internet-access-2000-2015/.

17.

• Levine DM, Lipsitz SR, Linder JA. Trends in seniors’ use of digital health technology in the United States 2011-2014. JAMA. 2016;316:538–40. Increasing older adult use of technologies for healthcare purposes. CrossRefPubMed

18.

Clauser SB, Wagner EH, Bowles EJA, Tuzzio L, Greene SM. Improving modern cancer care through information technology. Am J Prev Med. 2011;40(5):S198–207. https://doi.org/10.1016/j.amepre.2011.01.014.CrossRefPubMedPubMedCentral

19.

Zhou C, Crawford A, Serhal E, Kurdyak P, Sockalingam S. The impact of project ECHO on participant and patient outcomes: a systematic review. Acad Med J Assoc Am Med Coll. 2016;91:1439–61.CrossRef

20.

Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 191–205.

21.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55. https://doi.org/10.1097/00000421-198212000-00014.

22.

Puts MTE, Monette J, Girre V, Pepe C, Monette M, Assouline S, et al. Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol. 2011;78(2):138–49. https://doi.org/10.1016/j.critrevonc.2010.04.003.

23.

PACE participants, Audisio RA, Pope D, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol. 2008;65:156–63.CrossRef

24.

Kothari A, Phillips S, Bretl T, Block K, Weigel T. Components of geriatric assessments predict thoracic surgery outcomes. J Surg Res. 2011;166:5–13.CrossRefPubMed

25.

Efficace F, Novik A, Vignetti M, Mandelli F, Cleeland CS. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here? Haematologica. 2007;92:1596–8.CrossRefPubMed

26.

• Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, et al. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38:1184–90. Polypharmacy is common and associated with higher mortality in older patients with AML.

27.

Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med. 2010;40(11):1797–810. https://doi.org/10.1017/S0033291709992285.CrossRefPubMedPubMedCentral

28.

Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, et al. Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One. 2014;9(12):e115060. https://doi.org/10.1371/journal.pone.0115060.

29.

Ferrat E, Paillaud E, Caillet P, et al. Performance of four frailty classifications in older patients with cancer: prospective elderly cancer patients cohort study. J Clin Oncol. 2017;35:766–77.CrossRefPubMed

30.

Feng MA, McMillan DT, Crowell K, Muss H, Nielsen ME, Smith AB. Geriatric assessment in surgical oncology: a systematic review. J Surg Res. 2015;193(1):265–72. https://doi.org/10.1016/j.jss.2014.07.004.CrossRefPubMed

31.

Neuman HB, Weiss JM, Leverson G, O’Connor ES, Greenblatt DY, LoConte NK, et al. Predictors of short-term post-operative survival after elective colectomy in colon cancer patients ≥80 years of age. Ann Surg Oncol. 2013;20(5):1427–35. https://doi.org/10.1245/s10434-012-2721-8.

32.

Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, et al. Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol. 2012;126(1):20–4. https://doi.org/10.1016/j.ygyno.2012.04.019.

33.

• Loh KP, Magnuson A, Dale W, et al. Association of patient age, function and cognition with cancer treatment decisions: a University of Rochester NCORP study. J Clin Oncol. 2016;34. https://doi.org/10.1200/JCO.2016.34.15_suppl.10038. Low percentage of community oncologists utilized a geriatric assessment in routine practice.

34.

Mohile S, Magnuson S, Pandya C, Velarde C, Duberstein P, Hurria A, et al. Community Oncologists’ Decision-Making For Treatment of Older Patients with Cancer. J Natl Compr Canc Netw. 2018. (in press).

35.

Hurria A, Cirrincione CT, Muss HB, Kornblith AB, Barry W, Artz AS, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol. 2011;29(10):1290–6. https://doi.org/10.1200/JCO.2010.30.6985.

36.

•• Hurria A, Akiba C, Kim J, et al. Reliability, validity, and feasibility of a computer-based geriatric assessment for older adults with cancer. J Oncol Pract. 2016;12:e1025–34. Computer-based geriatric assessment is feasible in the geriatric oncology population. CrossRefPubMedPubMedCentral

37.

• Bhatt G, Hofmeister CC, Efebera YA, et al. A feasibility study of electronic geriatric assessment for real-time morbidity evaluation. J Clin Oncol. 2016;34. https://doi.org/10.1200/JCO.2016.34.15_suppl.e21523. Electronic geriatric assessment is feasible in patients with hematologic malignancies.

38.

• McCleary NJ, Wigler D, Berry D, et al. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013;18:64–72. Computer-based geriatric assessment is feasible in patients with gastrointestinal cancer, but half required resistance completing the assessment. CrossRefPubMedPubMedCentral

39.

•• Shahrokni A, Tin A, Downey RJ, Strong V, Mahmoudzadeh S, Boparai MK, et al. Electronic rapid fitness assessment: a novel tool for preoperative evaluation of the geriatric oncology patient. J Natl Compr Cancer Netw. 2017;15:172–9. Electronic geriatric assessment integrated with the electronic medical record is feasible.

40.

Nathwani N, Mohile SG, Lipe B, Carig K, DiGiovanni L, Davis A, et al. Integrating a touchscreen-based brief geriatric assessment in older adults with multiple myeloma. J Clin Oncol. 2017;35:e21703–3.

41.

Horgan AM, Seruga B, Pond GR, Alibhai SM, Amir E, De Wit R, et al. Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol. 2014;5(2):119–26. https://doi.org/10.1016/j.jgo.2013.12.001.

42.

Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer And Leukemia Group B experience. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:3699–704.

43.

• Stinchcombe TE, Zhang Y, Vokes EE, et al. Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute cooperative group studies. J Clin Oncol Off J Am Soc Clin Oncol. 2017; https://doi.org/10.1200/JCO.2016.71.4758. Older adults with cancer derived benefits from treatment but experienced increased toxicity.

44.

Quoix E, Zalcman G, Oster J-P, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet Lond Engl. 2011;378(9796):1079–88. https://doi.org/10.1016/S0140-6736(11)60780-0.

45.

Cataldo JK, Paul S, Cooper B, et al. Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer. 2013;13:6.CrossRefPubMedPubMedCentral

46.

Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993;119(2):121–6. https://doi.org/10.7326/0003-4819-119-2-199307150-00005.CrossRef

47.

Jensen RE, Snyder CF, Abernethy AP, Basch E, Potosky AL, Roberts AC, et al. Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract. 2014;10:e215–e222.

48.

•• Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2015; https://doi.org/10.1200/JCO.2015.63.0830. Electronic symptom monitoring improved health-related quality of life, reduced emergency room visits, and reduced hospitalizations.

49.

•• Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017; https://doi.org/10.1001/jama.2017.7156. Electronic symptom monitoring improved overall survival.

50.

Kearney N, McCann L, Norrie J, Taylor L, Gray P, McGee-Lennon M, et al. Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2009;17:437–44.

51.

McCann L, Maguire R, Miller M, Kearney N. Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl). 2009;18(2):156–64. https://doi.org/10.1111/j.1365-2354.2008.00938.x.CrossRef

52.

Maguire R, Fox PA, McCann L, Miaskowski C, Kotronoulas G, Miller M, et al. The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer. BMJ Open. 2017;7(5):e015016. https://doi.org/10.1136/bmjopen-2016-015016.

53.

Increased use of oral chemotherapy drugs spurs increased attention to patient compliance. J Oncol Pract. 2008;4:175–7. https://doi.org/10.1200/JOP.0843002.

54.

Ziller V, Kalder M, Albert U-S, Holzhauer W, Ziller M, Wagner U, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2009;20:431–6.

55.

Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–76. https://doi.org/10.1634/theoncologist.2015-0405.

56.

•• Puts MTE, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, et al. A systematic review of factors influencing older adults’ decision to accept or decline cancer treatment. Cancer Treat Rev. 2015;41:197–215. Adherence rates to cancer treatment vary across patients.

57.

Stilley CS, Bender CM, Dunbar-Jacob J, Sereika S, Ryan CM. The impact of cognitive function on medication management: three studies. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2010;29:50–5.

58.

• Loh KP, Pandya C, Zittel J, et al. Associations of sleep disturbance with physical function and cognition in older adults with cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2017; https://doi.org/10.1007/s00520-017-3724-6. Almost 50% of patients referred to a geriatric oncology were screened positive for cognitive impairment.

59.

Bennett JA, Cameron LD, Whitehead LC, Porter D. Differences between older and younger cancer survivors in seeking cancer information and using complementary/alternative medicine. J Gen Intern Med. 2009;24(10):1089–94. https://doi.org/10.1007/s11606-009-0979-8.CrossRefPubMedPubMedCentral

60.

Fitzpatrick AL, Powe NR, Cooper LS, Ives DG, Robbins JA. Barriers to health care access among the elderly and who perceives them. Am J Public Health. 2004;94(10):1788–94. https://doi.org/10.2105/AJPH.94.10.1788.CrossRefPubMedPubMedCentral

61.

Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15(5):507–22. https://doi.org/10.1634/theoncologist.2009-0290.CrossRefPubMedPubMedCentral

62.

Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22. https://doi.org/10.1177/2042098615615472.CrossRefPubMedPubMedCentral

63.

Marcum ZA, Gellad WF. Medication adherence to multi-drug regimens. Clin Geriatr Med. 2012;28(2):287–300. https://doi.org/10.1016/j.cger.2012.01.008.CrossRefPubMedPubMedCentral

64.

Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM. Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 2016;7(5):346–53. https://doi.org/10.1016/j.jgo.2016.07.010.CrossRefPubMedPubMedCentral

65.

• Neugut AI, Zhong X, Wright JD, Accordino M, Yang J, Hershman DL. Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol. 2016;2:1326–32. Nonadherence to chronic medications was associated with nonadherence to oral hormonal therapy. CrossRefPubMed

66.

DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794–811. https://doi.org/10.1097/00005650-200209000-00009.CrossRefPubMed

67.

Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(9):1053–9. https://doi.org/10.1200/JCO.2014.58.3062.CrossRef

68.

Spoelstra SL, Given CW. Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs. 2011;27(2):116–32. https://doi.org/10.1016/j.soncn.2011.02.004.CrossRefPubMed

69.

•• Burhenn PS, Smudde J. Using tools and technology to promote education and adherence to oral agents for cancer. Clin J Oncol Nurs. 2015;19:53–9. A literature search on the tools and technology for promoting adherence to oral cancer treatments. CrossRefPubMed

70.

•• Mislang AR, Wildes TM, Kanesvaran R, Baldini C, Holmes HM, Nightingale G, et al. Adherence to oral cancer therapy in older adults: the International Society of Geriatric Oncology (SIOG) taskforce recommendations. Cancer Treat Rev. 2017;57:58–66. Recommendations from SIOG on adherence to oral cancer treatment.

71.

de Figueiredo Junior AG, Forones NM. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer. Arq Gastroenterol. 2014;51:186–91.CrossRefPubMed

72.

Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M. How we will treat chronic myeloid leukemia in 2016. Blood Rev. 2015;29(2):137–42. https://doi.org/10.1016/j.blre.2014.12.003.CrossRefPubMed

73.

Vitality - NantHealth. https://nanthealth.com/vitality/. Accessed 7 Sep 2017.

74.

Improving medication adherence for oncology patients through high-tech interventions. In: Spec. Pharm. Times. https://www.specialtypharmacytimes.com/publications/specialty-pharmacy-times/2015/june-2015/improving-medication-adherence-for-oncology-patients-through-high-tech-interventions. Accessed 7 Sep 2017.

75.

Rogers WA, Fisk AD. Toward a psychological science of advanced technology design for older adults. J Gerontol B Psychol Sci Soc Sci. 2010;65B(6):645–53. https://doi.org/10.1093/geronb/gbq065.CrossRefPubMedCentral

76.

• Evans J, Papadopoulos A, Silvers CT, Charness N, Boot WR, Schlachta-Fairchild L, et al. Remote health monitoring for older adults and those with heart failure: adherence and system usability. Telemed J E Health. 2016;22:480–8. A number of issues specific to older adults were identified when studying technology use in this population.

77.

• Chaudhuri S, Thompson H, Demiris G. Fall detection devices and their use with older adults: a systematic review. J Geriatr Phys Ther. 2014;37:178–96. Challenges encountered when studying technology use in older adults. CrossRefPubMedPubMedCentral

78.

Charness N, Boot WR. Aging and information technology use potential and barriers. Curr Dir Psychol Sci. 2009;18(5):253–8. https://doi.org/10.1111/j.1467-8721.2009.01647.x.CrossRef

Title: Using Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients
Authors: Kah Poh Loh
Colin McHugh
Supriya G. Mohile
Karen Mustian
Marie Flannery
Heidi Klepin
Rebecca Schnall
Eva Culakova
Erika Ramsdale
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Oncology Reports / Issue 3/2018
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-018-0672-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia

Electronic Assessment of Physical Decline in Geriatric Cancer Patients

Melanoma and Immune Checkpoint Inhibitors

Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors

Exercise Training and Cardiovascular Health in Cancer Patients

Mucosal Melanoma: a Literature Review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer